Financial Performance

Blue Jet Healthcare reported FY25-26 revenue of ₹9,473.21 million (down 8% from ₹10,299.85 million in FY25) and Profit After Tax of ₹2,478.16 million (down 18.8% from ₹3,052.03 million). The decline was primarily due to customer inventory destocking in the Pharma Intermediates & API segment. Basic EPS stood at ₹14.29 (down from ₹17.59), with EBITDA margin at 31% and PAT margin at 26%.

Capital Structure & Dividend

The company maintained a zero debt position and raised ₹8,000 million through QIP issuance of 15,810,276 equity shares at ₹506 per share. A final dividend of ₹1.20 per equity share (60% of face value) was recommended for shareholder approval. Public shareholding increased to 26.85% post-QIP, complying with minimum public shareholding requirements.

Operational Expansion & Investments

Significant capital expenditure of ₹3,014 million is in progress, including:

  • Vizag Greenfield Project: Acquired 102.48 acres with Phase 1 investment approved at ₹1,000 crore over three years
  • Hyderabad R&D Center: Secured for GLP-1 intermediates and peptide chemistry with ₹400 million investment
  • Mahad Facility: Backward integration project for contrast media raw materials
  • Plant 6 at Ambernath: Successfully commissioned during FY25

Corporate Governance & Compliance

Auditors issued an unqualified opinion but noted title deeds for properties worth ₹605.82 million remain in the name of merged entity Blue Circle Organics. Income tax disputes amounting to ₹1,768.86 million are under appeal. The company maintains CARE A1+ (Short-term) and CARE A+ (Long-term) credit ratings and numerous regulatory accreditations including WHO-GMP and ISO certifications.

ESG & Operational Highlights

  • Environmental: 40% energy savings from renewables, GHG emissions reduced to 32,138.47 tCO2e
  • Social: CSR spend of ₹44.50 million, 37.5% women on Board, zero lost time injuries
  • Digital: Successful SAP S/4HANA implementation through Project LEAP
  • R&D: 63 professionals at BlueJet Advance Research Centre with ₹71.55 million expenditure

AGM & Corporate Actions

The 58th Annual General Meeting is scheduled for September 21, 2026, with key resolutions including:

  • Adoption of financial statements and dividend declaration
  • Re-appointment of directors including Mr. Naresh Suryakant Shah
  • Re-appointment of statutory auditors KKC & Associates LLP for a second 5-year term

Market Position & Outlook

The company exports ~90% of turnover to 50+ countries, serving innovator pharmaceutical companies and multinational generics. FY27 guidance anticipates mid-single digit growth in Contrast Media Intermediates with PI/API destocking cycle complete. Strategic focus remains on transitioning from service provider to strategic CDMO partner.